MedTrace Logo

Efficacy of Using Interleukin-2 in Antiretroviral Naïve HIV Patients (ANRS119)

NCT00120185 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2026-04-03

No results posted yet for this study

Summary

Interleukin-2 (IL-2) increases the number of CD4 cells in HIV-1 infected patients under highly active antiretroviral therapy (HAART) with a CD4 cell count over 200/mm3, but its activity in patients without antiretroviral therapy is unknown. This study will test the efficacy and safety of IL-2 in naïve patients with a CD4 count between 300 and 500/m3.

Conditions

  • HIV Infections

Interventions

DRUG

Interleukin-2

Sponsors & Collaborators

  • Chiron Corporation

    collaborator INDUSTRY

  • French National Agency for Research on AIDS and Viral Hepatitis

    lead OTHER_GOV

Principal Investigators

  • Jean-Michel Molina, MD · Hopital Saint Louis Paris service des Maladies infectieuses et Tropicales

  • Jean-Pierre Aboulker, MD · Inserm SC10

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-12-31
Primary Completion
2006-11-30
Completion
2006-11-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00120185 on ClinicalTrials.gov